Determination of domperidone in human plasma using high performance liquid chromatography with fluorescence detection for clinical application.

A simple and reliable method for the determination of domperidone in human plasma has been developed. Plasma samples (1mL) were pre-purified by a solid-phase extraction with Bond Elut(®) C18. The separation was achieved with XBridge™ C18 column (150mm×4.

Effects of dosing interval on the pharmacokinetic and pharmacodynamic interactions between the oral adsorbent AST-120 and triazolam in humans.

Objective: The objective of this study was to evaluate the pharmacokinetic and pharmacodynamic interactions between the oral adsorbent AST-120 and triazolam.

Methods: In this randomized, cross-over study, 12 healthy volunteers received a single oral dose of triazolam 0.25 mg alone or with AST-120 2 g given 0, 30 or 60 min before triazolam administration.

Itraconazole and domperidone: a placebo-controlled drug interaction study.

Purpose: To determine the influence of itraconazole on the pharmacokinetics, and the CNS and prolactin-elevating effects of domperidone in humans.

Methods: Fifteen healthy volunteers received either itraconazole (200 mg daily) or placebo for 5 days with a double blind, randomized, cross-over design. A single oral 20-mg dose of domperidone was administered to subjects on day 5.

The effects of the SLCO2B1 c.1457C > T polymorphism and apple juice on the pharmacokinetics of fexofenadine and midazolam in humans.

Objective: The objective was to determine the effects of the SLCO2B1 c.1457C> T polymorphism and apple juice on the pharmacokinetics of fexofenadine and midazolam in humans.

Methods: Individuals were divided based on the genotype of SLCO2B1 c.